Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness
A Randomized, Double-Blind, Placebo-Controlled Study Of A Fixed Dose Of Subcutaneous Methylnaltrexone In Adults With Advanced Illness And Opioid-Induced Constipation: Efficacy, Safety, And Additional Health Outcomes
Sponsor: Bausch Health Americas, Inc.
This PHASE4 trial investigates Opioid-Induced Constipation and is currently completed. Bausch Health Americas, Inc. leads this study, which shows 9 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2019 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Jun 2018 — Jun 2019 [monthly]
Completed PHASE4
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE4
-
Feb 2017 — Mar 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Jun 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bausch Health Americas, Inc.
- Progenics Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .